CHMP Pipeline Shift and Critical Medicines Act Mandates

Episode 26 — 09 June 2026 CHMP's May approvals reveal a structural shift toward rare disease development while the Critical Medicines Act introduces mandatory supply chain transparency requirements. AI maintains its dominance in HEOR methodology as NICE expands cardiovascular and digital health guidance. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Transcript

SPEAKER_00 0:00

Welcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus with Sarah. Today, CHMP's structural shift in European approvals, the Critical Medicines Act's mandatory compliance framework, and AI's continued HEOR dominance. Let's get into it.

SPEAKER_01 0:17

The CHMP's May session delivered eight new approvals with 42% carrying orphan designation. That's not just a statistical quirk. Clinical trial Vanguard is calling it a structural shift in European drug development.

SPEAKER_00 0:30

The evidence requirements tell the story. JASCAID for idiopathic pulmonary fibrosis via Joyce under conditional authorization for PIC3 CA disorders. These are molecularly targeted, rare indications demanding sophisticated HEOR packages that most companies can't deliver.

SPEAKER_01 0:47

But here's where I push back on the narrative. Yes, we're seeing more orphan designations, but that doesn't necessarily mean a structural shift. It could simply reflect what's coming through the pipeline now. Investments made five to seven years ago when rare disease looked attractive.

SPEAKER_00 1:02

The 42% figure from 2025 suggests this isn't a blip. When nearly half of new approvals require orphan-level evidence generation, that fundamentally changes how evidence teams need to be structured. Small patient populations, natural history studies, external controls, completely different skill sets.

SPEAKER_01 1:22

Fair point on the skill sets, but I'd argue the real structural shift is regulatory, not commercial. EMA's comfort with conditional authorizations and accelerated pathways is what's enabling these approvals. The pipeline follows the regulatory incentives.

SPEAKER_00 1:37

Either way, if you're not building rare disease HEOR capabilities, you're increasingly irrelevant to European approvals. The oral semaglutide approval is the exception proving the rule, a major population indication in a sea of molecular targets.

SPEAKER_01 1:51

Now the Critical Medicines Act brings mandatory supply chain transparency requirements. The provisional political agreement expands EMA's mandate to assess 200-plus active substances for vulnerability. This isn't voluntary compliance anymore.

SPEAKER_00 2:05

The shift from voluntary to mandatory changes everything for evidence strategy. When EMA conducts supply chain vulnerability assessments that directly influence pricing negotiations, you need to factor resilience metrics into your value propositions from the start.

SPEAKER_01 2:20

But here's my concern. We're adding another layer of complexity without clear evidence it solves the actual problem. Supply shortages happen for economic reasons, not information asymmetries. More EMA assessments won't fix fundamental market dynamics.

SPEAKER_00 2:35

I disagree. Information asymmetries are exactly the problem. Payers can't make rational resilience trade-offs without understanding vulnerability. The 200 plus substance mandate gives them that data.

SPEAKER_01 2:46

Or it gives them another tool to pressure prices downward while claiming it's about supply security. The contracting authority requirements for procurement procedures sound like disguised price controls to me.

SPEAKER_00 2:57

Maybe, but the alternative is continued ad hoc shortages, um, disrupting patient care. At least this creates predictable requirements companies can plan around.

SPEAKER_01 3:11

Moving to methodology, AI maintains the top spot in ISPOR's 2026 to 2027 trends, rising from third place. The emphasis on governance and human oversight suggests the field is maturing beyond the initial hype.

SPEAKER_00 3:25

Nice citing ISPOR's Palisade checklist in its AI policy shows real operational impact. When HTA bodies start referencing specific AI frameworks, that's institutional adoption, not just trend watching.

SPEAKER_01 3:37

Absolutely.

SPEAKER_00 3:52

The combination with real-world evidence in second place makes sense. AI enables the RWE analyses the traditional methods couldn't handle at scale.

SPEAKER_01 4:01

True, though I wonder if we're creating new validation challenges. AI-generated insights from RWE datasets sound impressive, but regulatory comfort with those methods is still evolving.

SPEAKER_00 4:11

Finally, NICE's semaglutide guidance for cardiovascular risk reduction reflects their continued expansion into prevention-oriented indications. The health economic modeling for cardiovascular event prevention requires much longer time horizons than traditional treatment indications.

SPEAKER_01 4:28

The digital health technology guidance for asthma self-management is equally significant. NICE is systematically building its digital health assessment capabilities, creating new evidence requirements companies aren't prepared for.

SPEAKER_00 4:41

Between rare disease complexity, supply chain mandates, AI governance, and digital health assessment, the evidence requirements are fragmenting across multiple specialized domains.

SPEAKER_01 4:51

Which brings us back to structural shifts. The CHMP approvals might be following pipeline trends, but the regulatory and HTA environment is definitely transforming. Companies that don't adapt their evidence capabilities will find themselves increasingly excluded.

SPEAKER_00 5:07

Back tomorrow on Access Brief, show notes at outcomes analytica.no.